Clinical Trials Logo

Clinical Trial Summary

The purpose of this project is to present the outcomes of patients with giant cell tumor of bone (GCTB) who were treated with surgery and/or medical treatment in a single institution.


Clinical Trial Description

The investigators retrospectively review patients treated for GCTB of the extremities between 1990 and 2013 in a single institution. We evaluate the recurrence free survival rate after surgical and medical treatment of patients with GCTB of the extremities to determine the influence of the surgical approach, denosumab therapy, local tumor presentation, and demographic factors on the risk of recurrence. ;


Study Design

Observational Model: Case-Only, Time Perspective: Retrospective


Related Conditions & MeSH terms


NCT number NCT02996734
Study type Observational
Source Istituto Ortopedico Rizzoli
Contact
Status Completed
Phase N/A
Start date April 2016
Completion date December 2016

See also
  Status Clinical Trial Phase
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Active, not recruiting NCT04255576 - Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone Phase 1/Phase 2
Completed NCT03301857 - Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Phase 4
Completed NCT05402865 - A Real-world Study on Patients of Unresectable Giant Cell Tumor of Bone
Recruiting NCT03295981 - Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone Phase 3
Completed NCT00464620 - Trial of Dasatinib in Advanced Sarcomas Phase 2
Recruiting NCT03259152 - Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone Phase 3
Recruiting NCT05595603 - Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage Phase 2
Not yet recruiting NCT03358212 - Safety and Efficacy of Post-operative Denosumab Strategy for Giant Cell Tumor of Bone Treatment in China N/A
Completed NCT04002817 - Giant Cell Tumor of the Bone in Young Patients
Completed NCT00396279 - Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone Phase 2
Terminated NCT00889590 - Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT) Phase 2
Recruiting NCT04586660 - Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone Phase 4
Active, not recruiting NCT03449108 - LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas Phase 2
Not yet recruiting NCT05813665 - A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone Phase 3